MTTI at the 2nd Annual Targeted Radionuclide Pharmaceuticals Supply Chain & Manufacturing Summit
EQT Life Sciences-led Oversubscribed Funding Round Raises EUR134 Million
EQT Leads $102.5 Mln Series A Funding Round in Belgian Radioisotope Producer PanTera
IBA's Joint Venture PanTera Secures EUR 93 Million in Oversubscribed Series A Round to Accelerate Global Actinium-225 Production
Perspective Gets FDA Fast Track Status for Radiopharmaceutical VMT101
Abdera Therapeutics Announces FDA Orphan Drug Designation for ABD-147 for the Treatment of Neuroendocrine Carcinoma
Novartis Expands U.S. Radiopharma Production Amid Rising Competition
QSA Global, Inc. and Niowave, Inc. Establish Collaboration to Improve Radium Purification, Increasing Radium Availability and Ac-225 Production
Blue Earth Therapeutics Ltd Announces Expansion of Partnership With Seibersdorf Labor GmbH to Include Manufacture of Therapeutic Radiopharmaceutical, 225Ac-rhPSMA-10.1
Actinium Pharmaceuticals, Inc. (ATNM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
B. Riley Downgrades Actinium Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $2 From $16
IONETIX Closes Financing Led by Tees River and Eli Lilly and Company
Express News | Actinium Pharmaceuticals Inc : Stephens Cuts Target Price to $5 From $25
Actinium Pharmaceuticals Price Target Cut to $4.00/Share From $50.00 by HC Wainwright & Co.
Actinium Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Maxim Group Maintains Actinium(ATNM.US) With Buy Rating
Maxim Group analyst Jason McCarthy maintains $Actinium(ATNM.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 23.3% and a total average return of -21.7% over the
Actinium Pharmaceuticals Shares Are Trading Higher After the Company Reported Better-than-expected Q2 EPS Results.
Actinium Pharmaceuticals Q2 2024 GAAP EPS $(0.38) Beats $(0.43) Estimate
Maxim Group Maintains Buy on Actinium Pharma, Lowers Price Target to $5
Actinium Pharma Analyst Ratings